{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T07:37:26Z","timestamp":1776843446305,"version":"3.51.2"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:00:00Z","timestamp":1595462400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>In December 2018, a large, tertiary, university-affiliated hospital in the Philippines discovered that their legitimate supply chain was infiltrated with counterfeit rabies vaccines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>All vials suspected to be counterfeit were quarantined and surrendered to the Philippine Food and Drug Administration. Patients who may have received the counterfeit products were recalled, evaluated, and revaccinated accordingly. Vials of the counterfeit vaccines were sent to various laboratories for testing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Two batches of counterfeit rabies vaccines were found to have infiltrated the hospital\u2019s supply chain between December 2017 and December 2018. Of the 1711 patients who may have received counterfeit vaccines, 1397 patients were successfully contacted, and 734 were revaccinated with at least 1 dose of authentic rabies vaccine. The counterfeit vials were sterile, contained no toxic substances, and both contained active antirabies ingredient. No report of rabies infection or other adverse events were noted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our experience demonstrates the need for strong intervention and collaborative response from all stakeholders\u2014government and regulatory bodies, the pharmaceutical industry, and individual institutions and consumers\u2014to effectively eradicate counterfeiting and protect our patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaa313","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T16:37:29Z","timestamp":1595522249000},"source":"Crossref","is-referenced-by-count":7,"title":["Counterfeit Rabies Vaccines: The Philippine Experience"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9468-7784","authenticated-orcid":false,"given":"Karl Evans R","family":"Henson","sequence":"first","affiliation":[{"name":"Hospital Infection Control and Epidemiology Center, The Medical City, Pasig City, Philippines"},{"name":"Section of Infectious Diseases, Department of Medicine, The Medical City, Pasig City, Philippines"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony Aldrin C","family":"Santiago","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Medical City, Pasig City, Philippines"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherilyne S","family":"Namqui","sequence":"additional","affiliation":[{"name":"Legal Services Department, The Medical City, Pasig City, Philippines"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,7,22]]},"reference":[{"key":"2020082210265475500_CIT0001","volume-title":"United Against Rabies Collaboration First annual progress report: global strategic plan to end human deaths from dog-mediated rabies by 2030","author":"World Health Organization, Food and Agriculture Organization of the United Nations, World Organization for Animal Health, Global Alliance for Rabies Control","year":"2019"},{"key":"2020082210265475500_CIT0002","first-page":"1","article-title":"Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices","volume":"59","author":"Rupprecht","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"2020082210265475500_CIT0003","author":"World Health Organization"},{"key":"2020082210265475500_CIT0004","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1016\/j.vaccine.2018.06.061","article-title":"Rabies vaccines: WHO position paper, April 2018 \u2013 recommendations","volume":"36","author":"World Health Organization","year":"2018","journal-title":"Vaccine"},{"key":"2020082210265475500_CIT0005","author":"World Health Organization"},{"key":"2020082210265475500_CIT0006","author":"National Institute of Infectious Diseases.","year":"2006"},{"key":"2020082210265475500_CIT0007","author":"Visperas","year":"2018"},{"key":"2020082210265475500_CIT0008","author":"Cordova"},{"key":"2020082210265475500_CIT0009","author":"Food and Drug Administration Philippines"},{"key":"2020082210265475500_CIT0010","author":"Food and Drug Administration Philippines"},{"key":"2020082210265475500_CIT0011","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1128\/IAI.16.3.754-759.1977","article-title":"Rabies virus glycoprotein. II. Biological and serological characterization","volume":"16","author":"Cox","year":"1977","journal-title":"Infect Immun"},{"key":"2020082210265475500_CIT0012","author":"World Health Organization"},{"key":"2020082210265475500_CIT0013","author":"Food and Drug Administration Philippines"},{"key":"2020082210265475500_CIT0014","author":"Food and Drug Administration Philippines"},{"key":"2020082210265475500_CIT0015","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/S1473-3099(06)70581-3","article-title":"Counterfeit anti-infective drugs","volume":"6","author":"Newton","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"2020082210265475500_CIT0016","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4269\/ajtmh.14-0389","article-title":"Counterfeit drug penetration into global legitimate medicine supply chains: a global assessment","volume":"92","author":"Mackey","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"2020082210265475500_CIT0017","first-page":"216","article-title":"The health and economic effects of counterfeit drugs","volume":"7","author":"Blackstone","year":"2014","journal-title":"Am Health Drug Benefits"},{"key":"2020082210265475500_CIT0018","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1128\/CMR.00072-14","article-title":"Substandard\/counterfeit antimicrobial drugs","volume":"28","author":"Kelesidis","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"2020082210265475500_CIT0019","author":"Food and Drug Administration Philippines"},{"key":"2020082210265475500_CIT0020","doi-asserted-by":"crossref","first-page":"e002923","DOI":"10.1136\/bmjopen-2013-002923","article-title":"Substandard and counterfeit medicines: a systematic review of the literature","volume":"3","author":"Almuzaini","year":"2013","journal-title":"BMJ Open"},{"key":"2020082210265475500_CIT0021","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.medmal.2012.04.007","article-title":"Update on counterfeit antibiotics worldwide; public health risks","volume":"42","author":"Delepierre","year":"2012","journal-title":"Med Mal Infect"},{"key":"2020082210265475500_CIT0022","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1371\/journal.pmed.0020100","article-title":"The global threat of counterfeit drugs: why industry and governments must communicate the dangers","volume":"2","author":"Cockburn","year":"2005","journal-title":"PLoS Med"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaa313\/33526199\/ofaa313.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/8\/ofaa313\/33674646\/ofaa313.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/8\/ofaa313\/33674646\/ofaa313.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T14:27:02Z","timestamp":1598106422000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaa313\/5875615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaa313","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8]]},"published":{"date-parts":[[2020,7,22]]},"article-number":"ofaa313"}}